nimacimab Updated Sep 13
Monitor the Q4 2026 Part C expansion topline data for nimacimab, which could drive value in the CVR. However, with the Redx reverse merger pending (expected Q4 2026 close), pre-merger SKYE shares now primarily represent ~5.38% of the future Fibrx Therapeutics, with nimacimab upside limited to the CVR, extreme caution is warranted for equity holders.
- nimacimab showed strong 52-week data: 22.3% mean weight loss in combination with semaglutide, a result that rivals or exceeds current GLP-1 monotherapy outcomes.
- As a peripheral CB1 inverse agonist, nimacimab has a novel mechanism orthogonal to GLP-1s, it could be a best-in-class oral or injectable add-on to existing obesity therapies.
- Analyst consensus remains bullish: 9 Buy/Strong Buy vs 3 Hold (0 Sell), with a mean price target of ~$68, median $48, and high of $160 (per latest snapshot as of Sep 2026).
- Skye announced a reverse merger with Redx Pharma on Aug 14, 2026; pre-transaction SKYE shareholders will own just ~5.38% of the combined Fibrx Therapeutics, representing extreme dilution, nimacimab is no longer the company's core asset, just a CVR.
- Cash runway only through Q4 2026 (excluding Phase 2b costs); the company had just $17.1M as of March 2026, raising serious financing risk for further nimacimab development.
- Significant insider selling by major holder 5AM Ventures (over 370K shares at ~$0.32-$0.38 in mid-August 2026) and elevated short volume ratio (~40% of session volume, per FINRA data).